Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Oruka Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oruka Therapeutics (ORKA), Alto Neuroscience, Inc. (...

Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA), Alto Neuroscience, Inc. (ANRO) and Astrana Health (ASTH)

Healthcare remains one of the market’s most steady sectors this year, backed by biotech innovation and medical device strength. According to analys...

3 Healthcare Stocks with Strong Upside to Consider in July 2026, According to Analysts

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Oruka Therapeutics (ORKA) and Hims &...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ORKA	$97.86	+11.12%	1.44M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ORKA	$97.86	+11.1%	1.44M
3
4
5
6

ORKA

ORKA

Get Oruka Therapeutics Inc. Data in Excel

Get Oruka Therapeutics Inc. Data in Excel